The RAPIDO trial—Reduction in disease‐related treatment failure does not translate into improved overall survival: a mystery solved
The initial publication of the RAPIDO trial resulted in widespread adoption of short‐course radiotherapy and consolidation chemotherapy in locally advanced rectal cancer. The impressive reduction in disease‐related treatment failure did not, however, translate into any overall survival benefit. The...
Gespeichert in:
| Veröffentlicht in: | Colorectal disease 2023-08, Vol.25 (8), p.1720-1721 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1721 |
|---|---|
| container_issue | 8 |
| container_start_page | 1720 |
| container_title | Colorectal disease |
| container_volume | 25 |
| creator | Ballal, Devesh Raj, Prudvi Saklani, Avanish P. |
| description | The initial publication of the RAPIDO trial resulted in widespread adoption of short‐course radiotherapy and consolidation chemotherapy in locally advanced rectal cancer. The impressive reduction in disease‐related treatment failure did not, however, translate into any overall survival benefit. The recent update of the RAPIDO trial with its 5‐year results provides much insight into the actual effect that this approach has on patient outcomes and the detriment in local control leads to the question as to whether this approach can still be considered as standard of care in high‐risk rectal cancer. |
| doi_str_mv | 10.1111/codi.16662 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2839741144</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2851008900</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3572-a391c3b623d39080f013c3f8bcc4717c0685a730ceb06f750530008e13e742133</originalsourceid><addsrcrecordid>eNp90U9rFDEYBvAgiq3Vix9AAl5EmPq-k5lkxlvZ-mehsFLqechm3sGUzKQmmS17682rBz9hP4nZbu3BQ3NIAvnl4YWHsdcIx5jXB-N7e4xSyvIJO8RKigIFNk_v7mXRtAgH7EWMlwAoFTbP2YFQlaxaKQ_Zr4sfxM9Pvi1PVzwFq93tzZ9z6meTrJ-4nXhvI-lItze_AzmdqM-MdBppSnzQ1s2BeO8p8smn_KSnuFP5Z_LcjlfBb_KXvAXtHI9z2NiNdh-55uM2JgpbHr3L5CV7NmgX6dX9ecS-f_50sfhanK2-LBcnZ4URtSoLLVo0Yi1L0YsWGhgAhRFDszamUqgMyKbWSoChNchB1VALAGgIBamqRCGO2Lt9bp7s50wxdaONhpzTE_k5dmUjWlUhVlWmb_-jl34OU54uqxpzbAuQ1fu9MsHHGGjoroIdddh2CN2unm5XT3dXT8Zv7iPn9Uj9A_3XRwa4B9fW0faRqG6xOl3uQ_8C1duciA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2851008900</pqid></control><display><type>article</type><title>The RAPIDO trial—Reduction in disease‐related treatment failure does not translate into improved overall survival: a mystery solved</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ballal, Devesh ; Raj, Prudvi ; Saklani, Avanish P.</creator><creatorcontrib>Ballal, Devesh ; Raj, Prudvi ; Saklani, Avanish P.</creatorcontrib><description>The initial publication of the RAPIDO trial resulted in widespread adoption of short‐course radiotherapy and consolidation chemotherapy in locally advanced rectal cancer. The impressive reduction in disease‐related treatment failure did not, however, translate into any overall survival benefit. The recent update of the RAPIDO trial with its 5‐year results provides much insight into the actual effect that this approach has on patient outcomes and the detriment in local control leads to the question as to whether this approach can still be considered as standard of care in high‐risk rectal cancer.</description><identifier>ISSN: 1462-8910</identifier><identifier>EISSN: 1463-1318</identifier><identifier>DOI: 10.1111/codi.16662</identifier><identifier>PMID: 37464966</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Chemotherapy ; DrTF in RAPIDO ; LARC standard of care ; OS in RAPIDO ; Radiation therapy ; RAPIDO explained ; RAPIDO mystery solved ; Rectum ; Survival</subject><ispartof>Colorectal disease, 2023-08, Vol.25 (8), p.1720-1721</ispartof><rights>2023 The Association of Coloproctology of Great Britain and Ireland.</rights><rights>Copyright © 2023 The Association of Coloproctology of Great Britain and Ireland</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3572-a391c3b623d39080f013c3f8bcc4717c0685a730ceb06f750530008e13e742133</citedby><cites>FETCH-LOGICAL-c3572-a391c3b623d39080f013c3f8bcc4717c0685a730ceb06f750530008e13e742133</cites><orcidid>0000-0002-7475-9509 ; 0000-0001-6472-7151 ; 0000-0003-4498-7612</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcodi.16662$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcodi.16662$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37464966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ballal, Devesh</creatorcontrib><creatorcontrib>Raj, Prudvi</creatorcontrib><creatorcontrib>Saklani, Avanish P.</creatorcontrib><title>The RAPIDO trial—Reduction in disease‐related treatment failure does not translate into improved overall survival: a mystery solved</title><title>Colorectal disease</title><addtitle>Colorectal Dis</addtitle><description>The initial publication of the RAPIDO trial resulted in widespread adoption of short‐course radiotherapy and consolidation chemotherapy in locally advanced rectal cancer. The impressive reduction in disease‐related treatment failure did not, however, translate into any overall survival benefit. The recent update of the RAPIDO trial with its 5‐year results provides much insight into the actual effect that this approach has on patient outcomes and the detriment in local control leads to the question as to whether this approach can still be considered as standard of care in high‐risk rectal cancer.</description><subject>Chemotherapy</subject><subject>DrTF in RAPIDO</subject><subject>LARC standard of care</subject><subject>OS in RAPIDO</subject><subject>Radiation therapy</subject><subject>RAPIDO explained</subject><subject>RAPIDO mystery solved</subject><subject>Rectum</subject><subject>Survival</subject><issn>1462-8910</issn><issn>1463-1318</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp90U9rFDEYBvAgiq3Vix9AAl5EmPq-k5lkxlvZ-mehsFLqechm3sGUzKQmmS17682rBz9hP4nZbu3BQ3NIAvnl4YWHsdcIx5jXB-N7e4xSyvIJO8RKigIFNk_v7mXRtAgH7EWMlwAoFTbP2YFQlaxaKQ_Zr4sfxM9Pvi1PVzwFq93tzZ9z6meTrJ-4nXhvI-lItze_AzmdqM-MdBppSnzQ1s2BeO8p8smn_KSnuFP5Z_LcjlfBb_KXvAXtHI9z2NiNdh-55uM2JgpbHr3L5CV7NmgX6dX9ecS-f_50sfhanK2-LBcnZ4URtSoLLVo0Yi1L0YsWGhgAhRFDszamUqgMyKbWSoChNchB1VALAGgIBamqRCGO2Lt9bp7s50wxdaONhpzTE_k5dmUjWlUhVlWmb_-jl34OU54uqxpzbAuQ1fu9MsHHGGjoroIdddh2CN2unm5XT3dXT8Zv7iPn9Uj9A_3XRwa4B9fW0faRqG6xOl3uQ_8C1duciA</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Ballal, Devesh</creator><creator>Raj, Prudvi</creator><creator>Saklani, Avanish P.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7475-9509</orcidid><orcidid>https://orcid.org/0000-0001-6472-7151</orcidid><orcidid>https://orcid.org/0000-0003-4498-7612</orcidid></search><sort><creationdate>202308</creationdate><title>The RAPIDO trial—Reduction in disease‐related treatment failure does not translate into improved overall survival: a mystery solved</title><author>Ballal, Devesh ; Raj, Prudvi ; Saklani, Avanish P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3572-a391c3b623d39080f013c3f8bcc4717c0685a730ceb06f750530008e13e742133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Chemotherapy</topic><topic>DrTF in RAPIDO</topic><topic>LARC standard of care</topic><topic>OS in RAPIDO</topic><topic>Radiation therapy</topic><topic>RAPIDO explained</topic><topic>RAPIDO mystery solved</topic><topic>Rectum</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ballal, Devesh</creatorcontrib><creatorcontrib>Raj, Prudvi</creatorcontrib><creatorcontrib>Saklani, Avanish P.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Colorectal disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ballal, Devesh</au><au>Raj, Prudvi</au><au>Saklani, Avanish P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The RAPIDO trial—Reduction in disease‐related treatment failure does not translate into improved overall survival: a mystery solved</atitle><jtitle>Colorectal disease</jtitle><addtitle>Colorectal Dis</addtitle><date>2023-08</date><risdate>2023</risdate><volume>25</volume><issue>8</issue><spage>1720</spage><epage>1721</epage><pages>1720-1721</pages><issn>1462-8910</issn><eissn>1463-1318</eissn><abstract>The initial publication of the RAPIDO trial resulted in widespread adoption of short‐course radiotherapy and consolidation chemotherapy in locally advanced rectal cancer. The impressive reduction in disease‐related treatment failure did not, however, translate into any overall survival benefit. The recent update of the RAPIDO trial with its 5‐year results provides much insight into the actual effect that this approach has on patient outcomes and the detriment in local control leads to the question as to whether this approach can still be considered as standard of care in high‐risk rectal cancer.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37464966</pmid><doi>10.1111/codi.16662</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-7475-9509</orcidid><orcidid>https://orcid.org/0000-0001-6472-7151</orcidid><orcidid>https://orcid.org/0000-0003-4498-7612</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8910 |
| ispartof | Colorectal disease, 2023-08, Vol.25 (8), p.1720-1721 |
| issn | 1462-8910 1463-1318 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2839741144 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Chemotherapy DrTF in RAPIDO LARC standard of care OS in RAPIDO Radiation therapy RAPIDO explained RAPIDO mystery solved Rectum Survival |
| title | The RAPIDO trial—Reduction in disease‐related treatment failure does not translate into improved overall survival: a mystery solved |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T02%3A21%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20RAPIDO%20trial%E2%80%94Reduction%20in%20disease%E2%80%90related%20treatment%20failure%20does%20not%20translate%20into%20improved%20overall%20survival:%20a%20mystery%20solved&rft.jtitle=Colorectal%20disease&rft.au=Ballal,%20Devesh&rft.date=2023-08&rft.volume=25&rft.issue=8&rft.spage=1720&rft.epage=1721&rft.pages=1720-1721&rft.issn=1462-8910&rft.eissn=1463-1318&rft_id=info:doi/10.1111/codi.16662&rft_dat=%3Cproquest_cross%3E2851008900%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2851008900&rft_id=info:pmid/37464966&rfr_iscdi=true |